Modis Therapeutics (A Zogenix Company) Revenue and Competitors

Modis Therapeutics is a wholly owned subsidiary of Zogenix, Inc. We are focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. Our lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. As a member of the Zogenix family, we arepassionate about taking on the complex challenges of developing therapeutic solutions with the potential to transform the lives of rare disease patients and their families. We strive to make a difference in the lives of these patients, their families, and our employees by operating ethically with the following values: - Compassion - We are driven to improve the lives of others. - Courage - We take action in the face of challenge or ambiguity. - Collaboration - We value the expertise of each individual. - Excellence - We strive to be the best that we can be. And we take pride in being a company that hires exceptional people - like you!